Derivative exercise or conversion — not an open-market buy.
Loading…
Traded Oct 6, 2026 · Filed Oct 6, 2026
Cytokinetics's Research & Development sold $215K of Cytokinetics shares. It happened by itself, for taxes or pay.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
open market sale
Code S — open-market or private sale
~$214,830
Shares × reported transaction price
61 days after results of Aug 6, 2026
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
Closed at $62.70 on Oct 5, 2026, 15% above its 52-week low and 28% below its high, after an 18% drop over the previous 30 trading days
52-week range $54.76 (Oct 22, 2025) to $87.26 (Jun 29, 2026), 24% of the way up, from 251 adjusted closes. 30 trading days earlier: $76.84 on Aug 21, 2026. Describes the past only, not a forecast
Filing box checked: sold under a Rule 10b5-1 plan
Only flagged when a footnote says so; never inferred
Derivative exercise or conversion — not an open-market buy.
Derivative exercise or conversion — not an open-market buy.
Derivative exercise or conversion — not an open-market buy.